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Dear Editor, 
 
We thank Professor Reich and colleagues for their correspondence on our paper (Jabbar-Lopez et 
al., 2017). They helpfully highlight the IXORA-S trial comparing ixekizumab with ustekinumab for 
moderate-severe plaque psoriasis (Reich et al., 2017). This was published after our search cut-off 
date and so was not included in our review.  
 
Reich et al. state that direct comparisons within a clinical trial provide the best evidence for evaluation 
of a drug. We agree that when a large (well-powered), high quality RCT has been performed the 
inclusion of indirect evidence adds little. However, IXORA-S was a trial of 302 participants and 
therefore underpowered to detect meaningful differences between treatments for less common 
outcomes, such as those related to safety. RCTs are not usually powered to show differences in 
adverse events (AEs) and so meta-analysis can be useful; by pooling data, power may be increased 
(Higgins JPT, 2011).  
 
Our NMA correctly estimated the efficacy of ixekizumab compared to ustekinumab at 12 weeks (NMA: 
OR 3.09, 95% CI 1.89, 5.06 compared to IXORA-S OR 3.67, 95% CI 2.25, 5.97) (Reichet al., 2017). 
This suggests that the analytical approach taken in our NMA is functioning correctly.  We know that 
the efficacy results from IXORA-S are likely to be correct as the study was powered to detect such a 
difference.  We can be less certain whether the IXORA-S estimates for withdrawal due to AEs are 
true (i.e. that there is no difference between withdrawal due to AE between ixekizumab and 
ustekinumab) or the result of type II error. Furthermore, Reich et al. have chosen to compare the 
results of our 12-16 week NMA to the 24-week results from IXORA-S. This time point was outside the 
scope of our NMA and not comparable to 12-16 week data. Considering just the 12-week data 
reported in Reich et al. 2017, the number of withdrawals due to AE was 0 (ustekinumab) and 2 
(ixekizumab). On the risk difference scale this equates to a 1% higher absolute risk of withdrawal due 
to AE (95% CI -1%, 4%) with ixekizumab versus ustekinumab, which is consistent with our NMA 
estimate of 2.5% (95% CI 0.6%, 6.3%), Table 1. Again, this suggests that the methodology is working. 
We state in our discussion that “The withdrawal due to adverse event results may be less reliable due 
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to the low number of events…” Furthermore, we highlight the low absolute numbers of events 
“(generally between 1 and 2%), reflected in the wide CI of the estimates”.  
We agree that considering any relative performance measure, whether pairwise odds ratios or ranking 
measures such as surface under the cumulative ranking curve (SUCRA), or probability of being best, 
in isolation, can be misleading. Hence, our efforts to provide both relative and absolute estimates for 
the outcomes. Two thirds of published NMAs include rankings (Bafeta et al., 2014) and expert groups 
such as the International Society for Pharmacoeconomics and Outcomes Research Task Force 
recommend ranking as a way of presenting NMA results (Jansen et al., 2011). The SUCRA accounts 
for the location and the variance of all relative treatment effects (Salanti et al., 2011) and as such the 
PRISMA-NMA statement and checklist (Item 13) encourage use of SUCRAs as a robust measure of 
ranking (Hutton et al., 2015).  This approach has been widely used in other NMAs, including for 
psoriasis (Gomez-Garcia et al., 2017), and Cochrane reviews in other fields, for example (Westby et 
al., 2017). Indeed, rankings have been used in an NMA focused solely 
on ixekizumab’s efficacy (Hartz et al., 2016) and this information was included in the 
single technology appraisal submission to the UK National Institute for Health and Care Excellence 
(2016).   
 
We chose withdrawal due to AEs as a proxy for tolerability following expert consensus. We agree that 
reasons for withdrawal due to AEs are important, however, these data were not consistently available 
from published studies. We thank Reich et al. for highlighting other (rare) safety outcomes (e.g. 
serious infections) and agree these data need to be considered when making treatment decisions, as 
discussed in our recent update to the British Association of Dermatologists guidelines for biologic 
therapy for psoriasis (Smith et al., 2017). However, these arguments do not mean the conclusions we 
made based on our NMA are incorrect (or that the methodology is flawed). 
 
In our discussion, and consistent with Figure 1 (Reich), we highlight that the differences in withdrawal 
due to AEs between the interventions were small in absolute terms e.g. 2.5% with ixekizumab 
compared to ustekinumab. While Figure 1 (Reich) accurately represents the data from our Table 1, it 
is not particularly helpful for clinicians or patients as +/- 50% risk difference of withdrawals due to 
adverse events would not be expected for approved treatments. We have re-plotted the graph with a 
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more clinically meaningful range of +/- 15% along with error bars from 95% confidence intervals, as 
even an absolute difference in risk of a few percent may be important for some patients. (Figure 1) 
 
We agree that the influence of dose on outcomes is important to consider and Reich et al. highlight 
the improvement in ixekizumab relative ranking from 7th to 6th in terms of tolerability when the analysis 
was restricted to licensed doses. Consistent with the approach taken in the cited recent pooled safety 
analysis of ixekizumab, we also considered it appropriate to include data from trials of non-label 
doses (Strober et al., 2017). As discussed, the differences may be true differences due to different 
doses, or may reflect the reduced precision seen in the smaller network of studies looking only at 
licensed doses, particularly for this less frequent outcome. Accordingly, we concluded that ‘data on 
tolerability should be interpreted cautiously’.  
 
In summary, our data analysis concurs with Reich’s and colleagues’ conclusion that ‘ixekizumab has 
a very high efficacy and is well tolerated’ (based on the absolute number of withdrawals due to AEs).  
However, we also consider the conclusions we made about the relative efficacy and tolerability of the 
different interventions, to be correct.   
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Figure 1: Efficacy compared to tolerability at Weeks 12 to 16 based on Figure 1 from Letter to 
the Editor by Reich et al* 
*Risk differences from Table 1 of Jabbar-Lopez et al. 
Abbreviations: ADA – adalimumab; ETA – etanercept; INF – infliximab; IXE – ixekizumab; MTX – 
methotrexate; PBO – placebo;  SEC – secukinumab; UST – ustekinumab 
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